New depression drug DT-101 enters Mid-Stage trial

NCT ID NCT07610473

Recruiting now Symptom relief Sponsor: Draig Therapeutics Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 7 times

Summary

This phase 2 trial tests whether DT-101 can ease depression symptoms in adults with major depressive disorder who are already on antidepressant medication. About 118 participants will receive either DT-101 or a placebo, and researchers will track changes in depression scores over 56 days. The goal is to see if DT-101 offers additional benefit beyond standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DT-101
What this could lead to: If it works, this could provide a new treatment option for people with major depressive disorder who are already on medication.
What could go wrong: This is an early-phase trial with only 118 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER (MDD)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Draig Clinical Site
RECRUITING

Phoenix, Arizona, 85013, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Little Rock, Arkansas, 72211, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Bellflower, California, 90706, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Costa Mesa, California, 92626, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Lafayette, California, 94549, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Hialeah, Florida, 33016, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Orlando, Florida, 32803, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Orlando, Florida, 32807, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Tampa, Florida, 33607, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Tampa, Florida, 33613, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Decatur, Georgia, 30030, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Chicago, Illinois, 60610, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Skokie, Illinois, 60076, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Boston, Massachusetts, 02130, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

New York, New York, 10025, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

New York, New York, 10029, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Columbus, Ohio, 43215, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Allentown, Pennsylvania, 18103, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Media, Pennsylvania, 19063, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

DeSoto, Texas, 75115, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Fort Worth, Texas, 76104, United States

Contact Email: •••••@•••••
Draig Clinical Site
RECRUITING

Bellevue, Washington, 98007, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.